In re HEXO Corp. Securities Litigation

CourtDistrict Court, S.D. New York
DecidedFebruary 25, 2020
Docket1:19-cv-10965
StatusUnknown

This text of In re HEXO Corp. Securities Litigation (In re HEXO Corp. Securities Litigation) is published on Counsel Stack Legal Research, covering District Court, S.D. New York primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
In re HEXO Corp. Securities Litigation, (S.D.N.Y. 2020).

Opinion

UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF NEW YORK -----------------------------------X RONNIE PEREZ, Individually and On Behalf of All Others Similarly Situated, MEMORANDUM AND ORDER

Plaintiff,

- against - 19 Civ. 10965 (NRB)

HEXO CORP., SÉBASTIEN ST. LOUIS, ED

CHAPLIN, MICHAEL MONAHAN, and STEVE

BURWASH

Defendants. ------------------------------------ GEORGE HUDAK, Individually and On

Behalf of All Others Similarly Situated,

Plaintiff, 20 Civ. 00196 (NRB) - against -

HEXO CORP., SÉBASTIEN ST. LOUIS, ED CHAPLIN, MICHAEL MONAHAN, and STEVE BURWASH,

Defendants. -----------------------------------X NAOMI REICE BUCHWALD UNITED STATES DISTRICT JUDGE

The above-captioned class actions (the “Actions”) are brought against HEXO Corp. (“HEXO”), its President and Chief Executive Officer Sébastien St. Louis, its Chief Financial Officers Ed Chaplin and Michael Monahan,1 and its Vice President of Strategic Finance Steve Burwash on behalf of a purported class of persons

1 According to the complaints filed in the above-captioned cases, Ed Chaplin served as Chief Financial Officer at all relevant times until May 2019 and Michael Monahan served as Chief Financial Officer from May 2019 through October 2019. and entities who acquired HEXO securities between January 25, 2019, and November 15, 2019, inclusive.2 The Actions allege violations of the Securities Exchange Act of 1934. For the reasons set forth below, the Court consolidates the Actions, appoints John B. Medley and Timothy Sweeney (“Medley and Sweeney”) as lead plaintiffs, and appoints Bernstein Liebhard LLP as lead counsel. DISCUSSION I. Consolidation of the Actions

As the Actions concern substantially the same factual and legal issues, the Court consolidates them under Rule 42(a) of the Federal Rules of Civil Procedure. See Atwood v. Intercept Pharm., Inc., 299 F.R.D. 414, 415 (S.D.N.Y. 2014). Any other securities actions now pending or later filed in this District that arise out of or are related to the same facts as alleged in the above cases shall be consolidated with the Actions for all purposes. All relevant filings and submissions shall be maintained as one file under docket number 19 Civ. 10965 with the caption In re HEXO Corp. Securities Litigation. II. Appointment of Lead Plaintiff

Eleven applicants filed motions seeking to consolidate these cases, be appointed as lead plaintiff, and appoint their attorneys

2 “HEXO is purportedly a licensed producer and distributor of branded cannabis products. The Company caters to both the medical and recreational (adult-use) cannabis markets with its Hydropothecary (medical) and HEXO (adult- use) brands.” ECF No. 1 ¶ 2. as lead counsel.3 Nine of those applicants subsequently withdrew their motions, see ECF Nos. 63-70, 72, leaving only the motions of Chi Fung Wong (“Wong”) and Medley and Sweeney in contention. Under the Private Securities Litigation Reform Act of 1995 (the “PSLRA”), in appointing a lead plaintiff, the Court is to presume that the “most adequate plaintiff” is the person or group of persons that: (aa) has either filed the complaint or made a motion in response to a notice [published by a complainant];

(bb) in the determination of the court, has the largest financial interest in the relief sought by the class; and

(cc) otherwise satisfies the requirements of Rule 23 of the Federal Rules of Civil Procedure.

15 U.S.C. § 78u–4(a)(3)(B)(iii)(I). With respect to the requirements of Rule 23, “typicality and adequacy of representation are the only provisions relevant to the determination of lead plaintiff under the PSLRA.” Shi v. Sina Corp., No. 05-2154, 2005 WL 1561438, at *2 (S.D.N.Y. July 1, 2005) (quoting In re Oxford Health Plans, Inc. Sec. Litig., 182 F.R.D.

3 The Court received timely motions to be appointed lead plaintiff from: (1) Maxwell Bergmann, represented by Wolf Haldenstein Adler Freeman & Herz LLP (ECF Nos. 19-21); (2) Franklin Espinal, represented by The Rosen Law Firm, P.A. (ECF Nos. 22-24); (3) Gary Leider, represented by Bragar, Eagel & Squire, P.C. (ECF Nos. 26-28); (4) Abe Kashani, represented by Scott+Scott Attorneys at Law LLP (ECF Nos. 29-32); (5) Michael Luca, represented by Hagens Berman Sobol Shapiro LLP (ECF Nos. 34-35, 40); (6) Anthony LaMarca and Edward Zhuo, represented by Glancy Prongay & Murray LLP (ECF Nos. 36, 38-39, 41); (7) Chi Fung Wong, represented by Levi & Korsinsky, LLP (ECF Nos. 37, 42-44); (8) Steven Ceresa, represented by Faruqi & Faruqi, LLP (ECF Nos. 45-48); (9) Timothy Sweeney and John B. Medley, represented by Bernstein Liebhard LLP (ECF Nos. 49- 50, 55); (10) Joseph E. Majocha, represented by Pomerantz LLP (ECF Nos. 51-52, 54, 56, 59; and (11) Dr. John M. Kihm, represented by Robbins Geller Rudman & Dowd LLP (ECF Nos. 57-58, 60). 42, 49 (S.D.N.Y. 1998)). “The typicality threshold is satisfied where the proposed lead plaintiff’s claims arise from the same conduct from which the other class members’ claims and injuries arise.” Teran v. Subaye, Inc., No. 11 Civ. 2614 (NRB), 2011 WL 4357362, at *5 (S.D.N.Y. Sept. 16, 2011) (internal quotation marks omitted). “The adequacy requirement is satisfied where (1) class counsel is qualified, experienced, and generally able to conduct the litigation, (2) there is no conflict between the proposed lead plaintiff and the members of the class, and (3) the proposed lead

plaintiff has a sufficient interest in the outcome of the case to ensure vigorous advocacy.” Foley v. Transocean Ltd., 272 F.R.D. 126, 131 (S.D.N.Y. 2011). In evaluating adequacy, courts also consider such factors as the “available resources and experience of the proposed lead plaintiff,” Blackmoss Inv., Inc. v. ACA Capital Holdings, Inc., 252 F.R.D. 188, 191 (S.D.N.Y. 2008), which serve as a proxy for the movant’s financial and legal sophistication and, in turn, the likelihood that the movant will play a meaningful role in limiting the “lawyer-driven litigation that the PSLRA was designed to curtail,” Iron Workers Local No. 25 Pension Fund v. Credit-Based

Asset Servicing & Securitization, LLC, 616 F. Supp. 2d 461, 464 (S.D.N.Y. 2009). See also In re Razorfish, Inc. Sec. Litig., 143 F. Supp. 2d 304, 307 (S.D.N.Y. 2001) (noting that the PSLRA sought to ensure that courts would appoint a lead plaintiff -- “frequently a large institution or otherwise sophisticated investor” –- who “would be motivated to act like a ‘real’ client, carefully choosing counsel and monitoring counsel’s performance to make sure that adequate representation [is] delivered at a reasonable price”). To that end, an investor seeking to be appointed lead plaintiff – - though he need only make a preliminary showing that he satisfies the requirements of Rule 23, see In re eSpeed, Inc. Sec. Litig., 232 F.R.D. 95, 102 (S.D.N.Y. 2005) -- “nonetheless need[s] to provide enough information to make [that] preliminary showing,”

Karp v. Diebold Nixdorf, Inc., No. 19 Civ. 6180 (LAP), 2019 WL 5587148, at *5 (S.D.N.Y. Oct. 30, 2019), adhered to on reconsideration, No. 19 Civ. 6180 (LAP), 2019 WL 6619351 (S.D.N.Y. Dec. 5, 2019).

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Varghese v. China Shenghuo Pharmaceutical Holdings, Inc.
589 F. Supp. 2d 388 (S.D. New York, 2008)
In Re Razorfish, Inc. Securities Litigation
143 F. Supp. 2d 304 (S.D. New York, 2001)
Miles v. Merrill Lynch & Co.
471 F.3d 24 (Second Circuit, 2006)
In re Initial Public Offering Securities Litigation
227 F.R.D. 65 (S.D. New York, 2004)
Pirelli Armstrong Tire Corp. v. LaBranche & Co.
229 F.R.D. 395 (S.D. New York, 2004)
In re eSpeed, Inc. Securities Litigation
232 F.R.D. 95 (S.D. New York, 2005)
Foley v. Transocean Ltd.
272 F.R.D. 126 (S.D. New York, 2011)
In re Gentiva Securities Litigation
281 F.R.D. 108 (E.D. New York, 2012)
Atwood v. Intercept Pharmaceuticals, Inc.
299 F.R.D. 414 (S.D. New York, 2014)

Cite This Page — Counsel Stack

Bluebook (online)
In re HEXO Corp. Securities Litigation, Counsel Stack Legal Research, https://law.counselstack.com/opinion/in-re-hexo-corp-securities-litigation-nysd-2020.